Preparation method and application of polyethylene glycol-modified lipid nanodisc with adjustable particle size
By regulating the proportion and concentration of long-chain and short-chain lipids, a polyethylene glycol modified lipid nanodisk with adjustable particle size was prepared, which solved the problem of difficult particle size regulation and poor stability in the prior art, and improved the drug The targeting efficiency and cell entry capability are suitable for hydrophobic drug delivery in the field of tumor treatment.
Patent Information
- Application Number
- CN202310054234.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-03
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-02-03
AI Technical Summary
The particle size of existing lipid nanodisks is not easy to regulate during the polyethylene glycol modification process and has poor stability, which affects the targeting efficiency and ability to enter the cell.
By regulating the ratio and concentration of long-chain lipids and short-chain lipids, polyethylene glycol modified lipid nanodisks with adjustable particle size were prepared, and dipalmitoylphosphatidylcholine and distearylphosphatidylethanolamine were used. - Components such as polyethylene glycol and dihexanoylphosphatidylcholine are formed by decompression rotary evaporation and ultrasonic treatment to form nanodisks to achieve accurate adjustment of particle size and stability improvement.
The particle size adjustment and stability are achieved, the targeting efficiency and cell entry capacity of drugs are improved, and it is suitable for hydrophobic drug delivery in the field of tumor treatment.
Smart Images

Figure CN116271087B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of novel preparations, relates to a lipid carrier, and specifically relates to a preparation method and application of a polyethylene glycol-modified lipid nanodisc with adjustable particle size. Background Art
[0002] Lipid nanocarriers are nanocarriers with phospholipids, cholesterol, etc. as the main components. Since phospholipids have an amphiphilic structure, lipid nanocarriers can be loaded with both hydrophilic and hydrophobic drugs [Expert Opin Drug Deliv. 2019 Nov;16(11):1205-1226.]. The most common lipid nanocarrier is a liposome with a phospholipid bilayer structure. Since liposomes are easy to prepare and industrially produce, a variety of liposome preparations are currently on the market. Especially in the field of tumor treatment, liposomes solve the difficulty of delivering some poorly soluble drugs and improve the delivery efficiency and bioavailability of drugs [Pharm Res. 2016 Oct;33(10):2373-87.].
[0003] Most of the liposome preparations currently on the market are multi-chamber liposomes. This type of liposome enhances the loading efficiency of hydrophobic drugs by increasing the lipid bilayer structure, but at the same time, the liposome particle size is also increasing significantly. Studies have shown that in the process of anti-tumor drug delivery, small-particle nanocarriers have better passive targeting and deep tumor penetration. The increase in the particle size of multi-chamber liposomes will reduce the targeting efficiency of drugs and affect the distribution of drugs in tumor sites [Adv Drug Deliv Rev. 2021 Sep;176:113851.]. In addition, liposomes are mostly modified with polyethylene glycol, which reduces the phagocytosis of drugs by reticuloendothelial cells during blood circulation, enhances blood circulation time, and prolongs half-life. However, polyethylene glycol modification will also reduce the cell uptake of liposomes and affect the efficiency of drug entry into cells [Pharmaceutics. 2020 Jun 10;12(6):533.].
[0004] Lipid nanodiscs, which also have a phospholipid bilayer structure, enhance the ability of drugs to enter cells by changing the shape of nanocarriers, and reduce the effect of nanodisc entry on cell entry by modifying the surface of the disk with polyethylene glycol [Biotechnol J. 2012 Jun; 7(6): 762-7.]. At present, lipid nanodiscs are mainly prepared by adjusting the ratio of long-chain lipids and short-chain lipids and changing the lipid type to achieve the preparation of nanodiscs with different requirements [Small-angle neutron scattering. Biophys J. 2002 May; 82(5): 2487-98.]. However, the ratio, concentration and lipid-drug molar ratio of the two lipids in the nanodisc affect the particle size and loading efficiency of the lipid nanodisc, and the ratio of long-chain lipids introduced to achieve polyethylene glycol modification affects the formation of lipid nanodiscs, resulting in the difficulty in regulating the particle size of polyethylene glycol-modified lipid nanodiscs during preparation and poor stability, which is prone to drug leakage.
[0005] How to develop a PEG-modified lipid nanodisc with adjustable particle size and good stability is a challenging task. Summary of the invention
[0006] The purpose of the present invention is to overcome at least one disadvantage of the prior art and provide a method for preparing polyethylene glycol-modified lipid nanodiscs with adjustable particle size and application thereof.
[0007] The present invention creatively proposes a method for preparing an improved polyethylene glycol-modified lipid nanodisc. By adjusting the ratio and concentration of long-chain lipids and short-chain lipids, the purpose of adjusting the size of the lipid nanodisc can be achieved, and lipid nanodiscs with adjustable particle size can be obtained. When the ratio of long-chain lipids to short-chain lipids increases, the particle size gradually increases; when the ratio remains unchanged, the particle size first increases and then decreases with the increase in concentration; and the stability is good for 7 days at a certain ratio and concentration.
[0008] The technical solution adopted by the present invention is:
[0009] The first aspect of the present invention provides: a method for preparing polyethylene glycol-modified lipid nanodiscs with adjustable particle size, comprising the following steps:
[0010] S1) preparing a lipid solution: dissolving dipalmitoylphosphatidylcholine, dihexanoylphosphatidylcholine and distearoylphosphatidylethanolamine-polyethylene glycol in an organic solvent to obtain a lipid solution, wherein the molar ratio of dipalmitoylphosphatidylcholine: distearoylphosphatidylethanolamine-polyethylene glycol: dihexanoylphosphatidylcholine is (6.3-7.2): (0.7-0.8): 1;
[0011] S2) removing the organic solvent in the lipid solution by rotary evaporation under reduced pressure to obtain a lipid film;
[0012] S3) adding deionized water to the lipid film to hydrate the film to obtain a hydration liquid, wherein the concentration of total phospholipids in the hydration liquid is 5 to 20%;
[0013] S4) The hydrated solution is sonicated to separate the lipid disks.
[0014] The long-chain phospholipids include DPPC and DSPE-PEG 2000, and the short-chain phospholipids refer to DHPC.
[0015] Preferably, the molar ratio (q) of the long-chain phospholipids to the short-chain phospholipids is 3-4.
[0016] More preferably, the molar ratio (q) of the long-chain phospholipids to the short-chain phospholipids is 3 to 3.5.
[0017] More preferably, the molar ratio (q) of the long-chain phospholipids to the short-chain phospholipids is 3.5.
[0018] Experimental data showed that as the molar ratio of dipalmitoylphosphatidylcholine:distearoylphosphatidylethanolamine-polyethylene glycol:dihexanoylphosphatidylcholine increased, the particle size of lipid nanodiscs increased; and as the total lipid concentration increased, the particle size of the nanodiscs increased. When it increased to 10%, the particle size of the nanodiscs reached its maximum and then gradually decreased.
[0019] The lipid concentration is the total lipid concentration after hydration.
[0020] Preferably, the lipid concentration is 20% to 5%.
[0021] More preferably, the lipid concentration is 10% to 5%.
[0022] More preferably, the lipid concentration is 5%.
[0023] In some examples of the preparation method, the temperature of the reduced pressure rotary evaporation is 42-47°C.
[0024] In some examples of the preparation method, the rotation speed of the reduced pressure rotary evaporation is 120 rpm to 150 rpm.
[0025] In some examples of the preparation method, the vacuum degree of the reduced-pressure rotary evaporation is 100 mbar to 450 mbar.
[0026] In some examples of the preparation method, the vacuum degree of the reduced pressure rotary evaporation is 100 mbar to 450 mbar, the water temperature is 42 to 47° C., the rotation speed is 120 rpm to 150 rpm, and the reduced pressure rotary evaporation time is 30 minutes to 80 minutes.
[0027] In some examples of the preparation method, at least one of the following conditions is met when the film is hydrated:
[0028] The water temperature is 42-47°C;
[0029] The speed is 120 rpm to 150 rpm;
[0030] The time is 20 to 50 minutes.
[0031] In some examples of the preparation method, the water temperature during the hydration of the film is 42-47° C., the rotation speed is 120 rpm-150 rpm, and the time is 20 minutes-50 minutes.
[0032] In some examples of the preparation method, the power of water bath ultrasound is 150 W to 600 W.
[0033] In some examples of the preparation method, the water bath ultrasonic power is 150 W to 600 W, the ultrasonic time is 1 to 3 minutes, the probe ultrasonic power is 50 W to 150 W, and the ultrasonic time is 1 to 3 minutes.
[0034] In some examples of the preparation method, the organic solvent is selected from chloroform and methanol.
[0035] In some examples of the preparation method, the distearoyl phosphatidylethanolamine-polyethylene glycol is distearoyl phosphatidylethanolamine-polyethylene glycol 2000.
[0036] The above technical features can be combined arbitrarily without conflict.
[0037] The particle size of the polyethylene glycol-modified lipid nanodisc prepared by any of the above methods is 10 to 100 nm.
[0038] The second aspect of the present invention provides: use of the lipid nanodiscs prepared by the preparation method described in the first aspect of the present invention as hydrophobic drug carriers.
[0039] The lipid nanodisc prepared by the present invention can be used to load hydrophobic small molecule drugs, and has a high encapsulation rate. The preparation method of the drug-loaded lipid nanodisc is to add a drug solution to the above-mentioned lipid solution, and obtain a stable drug-loaded lipid nanodisc by adjusting the molar ratio of the drug to the lipid. The preparation can be used for the delivery of various hydrophobic small molecule drugs, and has high practical value and development prospects in the field of tumor treatment.
[0040] In some application examples, the encapsulation efficiency of the hydrophobic drug is 85%-99%.
[0041] In some application examples, the hydrophobic drug is selected from doxorubicin, paclitaxel, docetaxel and the like.
[0042] The beneficial effects of the present invention are:
[0043] The preparation methods of some examples of the present invention can accurately adjust the particle size of lipid nanodisks by regulating the ratio and concentration of long-chain lipids and short-chain lipids. The preparation method has simple steps and is easy to operate. The materials used are all biocompatible materials with good safety. The prepared lipid nanodisks have uniform particle size and good stability.
[0044] The preparation methods of some examples of the present invention can prepare lipid nanodiscs with a particle size of 20-200 nm. The small particle size can penetrate deep into tumor tissue, thereby improving the application value of lipid nanodiscs in the field of anti-tumor drug delivery.
[0045] The lipid nanodiscs prepared by the preparation methods of some examples of the present invention are more convenient to prepare and store at room temperature, and the preparation methods are simple and more suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 TEM images of blank lipid nanodisks with different lipid ratios in Example 1 of the present invention.
[0047] Figure 2 : The particle size of blank lipid nanodiscs with different lipid ratios and concentrations in Example 1 of the present invention.
[0048] Figure 3 This is a graph showing the stability of blank lipid nanodisks at different lipid concentrations when q=3 in Example 1 of the present invention.
[0049] Figure 4 This is a graph showing the stability of blank lipid nanodisks at different lipid concentrations when q=3.5 in Example 1 of the present invention.
[0050] Figure 5 This is a graph showing the stability of blank lipid nanodisks at different lipid concentrations when q=4 in Example 1 of the present invention.
[0051] Figure 6 Transmission electron micrographs of doxorubicin-loaded lipid nanodiscs at different drug-to-lipid ratios in Example 2 of the present invention.
[0052] Figure 7 : The particle size and PDI distribution of doxorubicin-loaded lipid nanodiscs with different drug-to-lipid ratios in Example 2 of the present invention.
[0053] Figure 8 The encapsulation efficiency and drug loading of doxorubicin-loaded lipid nanodiscs with different drug-to-lipid ratios in Example 2 of the present invention are shown.
[0054] Fig. 9 This is a 9-day stability particle size distribution diagram of small-size doxorubicin-loaded lipid nanodisks in Example 2 of the present invention.
[0055] Fig.10 The 9-day stable drug loading and encapsulation efficiency of small-sized doxorubicin-loaded lipid nanodisks in Example 2 of the present invention. DETAILED DESCRIPTION
[0056] Abbreviations:
[0057] DPPC: 1,2-dihexadecanoyl-rac-glycero-3-phosp, dipalmitoylphosphatidylcholine
[0058] DSPE-PEG 2000: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-(polyethylene glycol)-2000
[0059] DHPC: 1,2-dihexanoyl-sn-glycero-3-phosphocholine.
[0060] The present invention is described in detail below through experimental implementation. It is necessary to point out that this example is only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Technical personnel skilled in the art can make some non-essential improvements and adjustments based on the above content of the present invention.
[0061] Example 1: Preparation of polyethylene glycol-modified lipid nanodiscs with adjustable particle size
[0062] Accurately weigh 0.0386 g DPPC, 0.0148 g DSPE-PEG and 0.0075 g DHPC and add them to a 50 mL eggplant-shaped bottle, add 5 mL chloroform solution to fully dissolve them. Rotate and evaporate under reduced pressure in a constant temperature water bath until a transparent film is obtained, and add 1 mL of deionized water to the eggplant-shaped bottle to hydrate the film. After hydration, use water bath ultrasound for 2 min, then use ice bath probe ultrasound (vibration 3 s, stop 2 s, power 90 w) for 2 min, filter with a 0.22 μm aqueous filter membrane to obtain a lipid nanodisc solution with uniform particle size, and store in a sealed container at 4°C.
[0063] Preliminary stability study of lipid nanodiscs with adjustable particle size
[0064] 100 μl of lipid nanodisc solution was taken at 1, 7, and 14 days, diluted 20 times with deionized water, and the particle size was measured by dynamic light scattering to determine its stability. The experimental results are shown in Tables 1 and 2. Figure 1 and Figure 2 Shown
[0065] Table 1. Particle size potential and PDI of blank lipid nanodisks
[0066]
[0067] Table 2. Summary of particle size (nm) of blank lipid nanodiscs at 1, 7, and 14 days
[0068]
[0069] Based on the experimental data, it can be seen that the q value has the most significant effect on the particle size of the nanodisk. When the q value is small (no more than 3.5), the particle size increases first and then decreases with the increase of the phospholipid concentration in the hydration liquid, and the particle size of the nanodisk is the smallest at a concentration of 10%; when the q value = 4, the particle size decreases with the increase of the phospholipid concentration in the hydration liquid.
[0070] Figure 1 TEM images of blank lipid nanodisks with different lipid ratios in Example 1 of the present invention.
[0071] Figure 2 is the particle size of blank lipid nanodiscs with different lipid ratios and concentrations in Example 1 of the present invention, group q=3: compared with the group with lipid concentration of 5.0% and 10.0%, * P <0.05; q=3.5 group: the group with lipid concentration of 5.0% compared with the other two groups, * P <0.05; q=4 group: the lipid concentration of the group with 5.0% was compared with that of the group with 2.5%, ** P <0.01, the lipid concentration of the group with 5.0% was compared with that of the group with 10.0%, * P <0.05, the lipid concentration of the group with 2.5% was compared with that of the group with 10.0%,*** P <0.001.
[0072] Figure 3 This is a graph showing the stability of blank lipid nanodisks at different lipid concentrations when q=3 in Example 1 of the present invention.
[0073] Figure 4 This is a graph showing the stability of blank lipid nanodisks at different lipid concentrations when q=3.5 in Example 1 of the present invention.
[0074] Figure 5 This is a graph showing the stability of blank lipid nanodisks at different lipid concentrations when q=4 in Example 1 of the present invention.
[0075] like Figure 1 Shown are transmission electron micrographs of blank lipid nanodisks with different lipid ratios. In the figure, it can be seen that in addition to the circular disk-like structure, there are also some side rod-like structures, which indicates the successful preparation of the lipid nanodisks.
[0076] like Figure 2 As shown, it is a graph of the particle size of nanodiscs at different q values and total lipid concentrations. It can be seen from the figure that the particle size of lipid nanodiscs is more appropriate when q=3 and q=3.5.
[0077] like Figure 3 , 4 As shown in Figures 5 and 6, when q = 3.5 and the lipid concentration is 5%, the stability of the lipid nanodiscs is the best, and the particle size does not change significantly at 1, 7, and 14 days.
[0078] Example 2: Preparation of small-size lipid nanodiscs loaded with doxorubicin
[0079] Accurately weigh 0.0386 g DPPC, 0.0148 g DSPE-PEG and 0.0075 g DHPC into a 50 mL eggplant-shaped bottle, add 4 mL chloroform solution to fully dissolve it; weigh 0.0040 g doxorubicin and dissolve it in 1 mL methanol, and add it to the eggplant-shaped bottle after it is fully dissolved. Rotate and evaporate under reduced pressure in a constant temperature water bath until a transparent red film is formed, and add 1 mL of deionized water to the eggplant-shaped bottle to hydrate the film. After hydration, ultrasonicate in a water bath for 2 min, then ultrasonicate with an ice bath probe (vibrate for 3 s, stop for 2 s, power of 90 w) for 2 min, and filter with a 0.22 μm aqueous filter membrane to obtain a uniform particle size doxorubicin-loaded lipid nanodisc solution, which is sealed and stored at 4 °C.
[0080] Preliminary stability study of doxorubicin-loaded lipid nanodiscs
[0081] 100 μl of doxorubicin-loaded lipid nanodisc solution was taken at 1, 3, 5, 7, and 9 days, diluted 20 times with deionized water, and the particle size was measured to determine its stability. Figures 3 to 9 As shown in Table 3.
[0082] Figure 6 Transmission electron micrographs of doxorubicin-loaded lipid nanodiscs at different drug-to-lipid ratios in Example 2 of the present invention. Figure 6 It reflects that lipid nanodiscs under electron microscopy have a circular disc structure and an elliptical side structure.
[0083] Figure 7 The particle size and PDI distribution of doxorubicin-loaded lipid nanodiscs with different drug-to-lipid ratios in Example 2 of the present invention are shown in Table 2. The particle size of the lipid nanodiscs with a drug-to-lipid ratio of 1:5 is *** P <0.001.
[0084] Figure 8 The encapsulation efficiency and drug loading of doxorubicin-loaded lipid nanodiscs with different drug-to-lipid ratios in Example 2 of the present invention are shown in Table 2. The particle size of the lipid nanodiscs with a drug-to-lipid ratio of 1:5 is 1:10, compared with that of the particle size of the lipid nanodiscs with a drug-to-lipid ratio of 1:5.P <0.001; the particle size of the drug-lipid ratio of 1:10 is compared with that of 1:15,### P <0.001; the particle size of the drug-lipid ratio of 1:5 is compared with that of 1:15,** P <0.01; Compared with the drug loading of the three, *** (###) P <0.001, all of them have significant differences.
[0085] Figure 7 and Figure 8 The particle size, PDI, drug loading and encapsulation efficiency proved that the drug-loaded lipid nanodiscs had the best properties when the drug-lipid ratio was 1:10.
[0086] Fig. 9 This is a 9-day stability particle size distribution diagram of small-size doxorubicin-loaded lipid nanodisks in Example 2 of the present invention.
[0087] Fig.10 The 9-day stable drug loading and encapsulation efficiency of small-sized doxorubicin-loaded lipid nanodisks in Example 2 of the present invention.
[0088] Fig. 9 , 10 It was demonstrated that the drug-loaded lipid nanodiscs had good stability within one week.
[0089] Table 3. Particle size potential and PDI of doxorubicin-loaded lipid nanodiscs with different drug-lipid ratios at q=3.5 and lipid concentration of 5% (n=3)
[0090]
[0091] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.
Claims
1. A method for preparing polyethylene glycol-modified lipid nanodiscs, comprising the following steps: S1) Prepare lipid solution: accurately weigh 0.0386 g DPPC, 0.0148 g DSPE-PEG and 0.0075 g DHPC into a 50 mL eggplant-shaped bottle, and add 5 mL chloroform solution to fully dissolve them; S2) rotary evaporation under reduced pressure in a constant temperature water bath until a transparent film is obtained to obtain a lipid film; S3) Add 1 mL of deionized water into the eggplant-shaped bottle to hydrate the film; S4) After hydration, ultrasonicate in a water bath for 2 min, and then ultrasonicate in an ice bath probe for 2 min. During the ultrasonication, vibrate for 3 s and stop for 2 s. The power is 90 W, and the lipid nanodisc solution with a 0.22 μm aqueous filter membrane is filtered to obtain a lipid nanodisc solution with uniform particle size; or S1) Accurately weigh 0.0386 g DPPC, 0.0148 g DSPE-PEG and 0.0075 g DHPC into a 50 mL eggplant-shaped bottle, add 4 mL chloroform solution to fully dissolve them; then weigh 0.0040 g doxorubicin and dissolve it in 1 mL methanol, and add it to the eggplant-shaped bottle after it is fully dissolved; S2) rotary evaporation under reduced pressure in a constant temperature water bath until a transparent red film is formed; S3) Add 1 mL of deionized water into the eggplant-shaped bottle to hydrate the film; S4) After hydration, ultrasonicate in a water bath for 2 min, and then ultrasonicate with an ice bath probe for 2 min. During the ultrasonication, vibrate for 3 s and stop for 2 s. The power is 90 W. Filter with a 0.22 μm aqueous filter membrane to obtain a doxorubicin-loaded lipid nanodisc solution with uniform particle size.
Citation Information
Patent Citations
Methods and devices for preparation of lipid nanoparticles
CN105188685A
Preparation method of long-circulation magnetic nano-liposomes in harmine
CN106265520A
Cation complex lipid nano disc as well as preparation method and application thereof
CN106834355A
Discoidal Nano Universal Platform for Efficient Delivery of PNAs
US20210369632A1
Nanodrugs for targeted drug delivery and use thereof
WO2022040435A1
